NEO
NeoGenomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$17.38
−0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 766.3M | 727.3M | 660.6M | 591.6M | 509.7M |
| Cost of Revenue | 437.4M | 444.8M | 370.5M | 347.0M | 321.8M |
| Gross Profit | 328.9M | 282.5M | 290.1M | 244.6M | 187.9M |
| Operating Expenses | |||||
| R&D Expense | 38.2M | 37.1M | 31.2M | 27.3M | 30.3M |
| SG&A Expense | 359.1M | 365.3M | 310.5M | 280.0M | 277.9M |
| General & Admin Expense | 262.7M | 273.3M | 225.9M | 209.1M | 210.6M |
| Selling & Marketing Expense | 96.4M | 92.0M | 84.6M | 70.8M | 67.3M |
| Other Expenses | (2.2M) | (53.8M) | 40.6M | 45.1M | 37.3M |
| Total Operating Expenses | 395.1M | 348.6M | 382.2M | 352.3M | 345.5M |
| Cost and Expenses | 832.5M | 793.4M | 752.7M | 699.4M | 667.4M |
| Operating Income (EBIT) | (66.2M) | (66.1M) | (92.1M) | (107.7M) | (157.6M) |
| Non-Operating | |||||
| Interest Income | 5.6M | 9.1M | 18.4M | 16.9M | 6.1M |
| Interest Expense | 2.6M | 3.8M | 6.6M | 6.9M | 7.6M |
| Net Interest Income | 3.0M | 5.3M | 11.8M | 10.0M | (1.5M) |
| Other Non-Op Income/Expense | 11.6M | (44.2M) | 11.4M | 10.6M | (1.7M) |
| Non-Operating Income (excl Interest) | (13.6M) | 40.4M | (18.0M) | (17.5M) | (5.9M) |
| EBT (Pre-Tax Income) | (54.5M) | (110.3M) | (80.7M) | (97.1M) | (159.3M) |
| Income Tax Expense | (2.7M) | (2.2M) | (1.9M) | (9.1M) | (15.1M) |
| Bottom Line | |||||
| Net Income | (51.9M) | (108.0M) | (78.7M) | (88.0M) | (144.3M) |
| Earnings from Cont. Ops | (51.9M) | (108.0M) | (78.7M) | (88.0M) | (144.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.9M) | (108.0M) | (78.7M) | (88.0M) | (144.3M) |
| Per Share | |||||
| Basic EPS | ($1.98) | ($4.20) | ($3.10) | ($3.50) | ($5.80) |
| Diluted EPS | ($1.98) | ($4.20) | ($3.10) | ($3.50) | ($5.80) |
| Revenue Per Share | $29.56 | $28.39 | $26.08 | $23.57 | $20.52 |
| Shares | |||||
| Basic Shares Outstanding | 25.9M | 25.6M | 25.3M | 25.1M | 24.8M |
| Diluted Shares Outstanding | 26.2M | 25.6M | 25.3M | 25.1M | 24.8M |
| Profitability Metrics | |||||
| EBITDA | 12.9M | (38.7M) | (1.5M) | (17.6M) | (82.3M) |
| D&A | 65.5M | 67.8M | 72.5M | 72.6M | 69.4M |
| EBIT | (52.6M) | (106.5M) | (74.1M) | (90.2M) | (151.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026